Novavax reported $-509067000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Adma Biologics ADMA:US $ -13.76M 4.57M
Agenus AGEN:US $ -49.24M 1.37M
AstraZeneca AZN:LN 258259.83M 36783.7M
Dynavax Technologies DVAX:US $ 129.37M 96.52M
Genocea Biosciences GNCA:US $ -15.98M 2.7M
Geron GERN:US $ -28.12M 1.98M
Mannkind MNKD:US $ -29.02M 3.02M
Minerva Neurosciences NERV:US $ -8.72M 1.05M
Novartis NVS:US $ 4129M 217M
Novavax NVAX:US $ -509.07M 715.14M
Pain Therapeutics PTIE:US $ -19.33M 1.8M
Peregrine Pharmaceuticals PPHM:US $ 2.27M 1.68M
Sanofi SAN:FP € 2660M 305M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M
Tg Therapeutics TGTX:US $ -40.51M 28.5M